Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,123 stopped studies mapped to Non-Small Cell Carcinoma and descendants · 90% state a reason
Over the 1,123 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01282151 | TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type…(TRAIL) | Phase 3 | terminated | Jan 24, 2011 | Chonnam National University Hospital | Difficulty in recruitment due to approval of maintenance pemetrexed treatment | Enrollment / accrual |
| NCT01928160 | Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride… | Phase 2 | withdrawn | Aug 23, 2013 | Vanderbilt-Ingram Cancer Center | study not accruing | Enrollment / accrual |
| NCT01685346 | Biofeedback Training in Patients With Advanced Lung Cancer - A Pilot Study | N/A | terminated | Sep 14, 2012 | Case Comprehensive Cancer Center | Research Cancelled | Other (stated, no rule matched) |
| NCT02368990 | T790M Mutation Positive 2nd Line STandard of cAre Registry(T-STAR) | — | withdrawn | Feb 23, 2015 | AstraZeneca | Since the conception of the study, the competitive environment has developed and as a result this… | Other (stated, no rule matched) |
| NCT00697060 | A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung… | Phase 2 | withdrawn | Jun 13, 2008 | AmpliMed Corporation | Study cancelled prior to start due to change in company priorities. | Sponsor / business decision |
| NCT00378404 | Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of… | Phase 1 | terminated | Sep 20, 2006 | Susanne Arnold | Slow accrual | Enrollment / accrual |
| NCT01222572 | Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Oct 18, 2010 | Dana-Farber Cancer Institute | Slow accrual due to restrictive eligibility criteria | Enrollment / accrual |
| NCT00431613 | Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without… | Phase 2 | terminated | Feb 6, 2007 | Hellenic Oncology Research Group | Due to Poor Accrual | Enrollment / accrual |
| NCT01720901 | Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine… | Phase 4 | suspended | Nov 2, 2012 | Betta Pharmaceuticals Co., Ltd. | Accrual limitations | Enrollment / accrual |
| NCT01038752 | Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer | Phase 2 | terminated | Dec 24, 2009 | Optimum Therapeutics, LLC | not stated | Not stated |
| NCT00238615 | Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC | Phase 2 | terminated | Oct 13, 2005 | Stanford University | low accrual | Enrollment / accrual |
| NCT00934076 | Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer | Phase 1 | withdrawn | Jul 8, 2009 | University of Alabama at Birmingham | Study was never activated | Other (stated, no rule matched) |
| NCT01893580 | Perioperative Rehabilitation in Operation for Lung Cancer(PROLUCA) | N/A | terminated | Jul 9, 2013 | Rigshospitalet, Denmark | Due to low recruiment rate, the study design is chanced to a feasibility study | Other (stated, no rule matched) |
| NCT01507740 | Profile of Soluble and Cellular Biomarkers and of Functional Imaging During… | — | terminated | Jan 11, 2012 | Medical University Innsbruck | Study was stopped 04.10.2014 prematurly after recruitment of HCC and RCC patients. NSCLC (2 of 10… | Enrollment / accrual |
| NCT00974662 | Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer | Phase 2 | terminated | Sep 10, 2009 | Steba Biotech S.A. | Early end of enrolment with regards to difficulty met to enrol patients. | Enrollment / accrual |
| NCT00903942 | Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | withdrawn | May 19, 2009 | University of Rochester | funding was withdrawn from Drug company | Funding |
| NCT01379976 | Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line… | Phase 3 | terminated | Jun 23, 2011 | Mario Negri Institute for Pharmacological Research | Recruitment was prematurely stopped due to difficulty of recruitment encountered by the… | Enrollment / accrual |
| NCT00707252 | Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer | Phase 1 | terminated | Jun 30, 2008 | Louisiana State University Health Sciences Center Shreveport | Phase II not initiated due to cancellation of supply of Poly E by collaborator. | Drug supply |
| NCT01714037 | A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of…(HALO) | Phase 1 | terminated | Oct 25, 2012 | Debiopharm International SA | not stated | Not stated |
| NCT00940875 | A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line… | Phase 2 | terminated | Jul 16, 2009 | Hoffmann-La Roche | Study was stopped due to slower than expected recruitment. | Enrollment / accrual |
| NCT00254891 | Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients… | Phase 3 | terminated | Nov 17, 2005 | Pfizer | See Termination Reason in Detailed Description | Other (stated, no rule matched) |
| NCT00254904 | Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in… | Phase 3 | terminated | Nov 17, 2005 | Pfizer | See Termination Reason in Detailed Description | Other (stated, no rule matched) |
| NCT02059967 | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients… | Phase 1 | withdrawn | Feb 11, 2014 | Virginia Commonwealth University | Due to no accrual. | Enrollment / accrual |
| NCT00251589 | A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With… | Phase 1 / Phase 2 | terminated | Nov 10, 2005 | Merck Sharp & Dohme LLC | This trial is being closed based on lack of substantive efficacy, slow accrual and overall… | Efficacy / futility |
| NCT01048983 | Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | withdrawn | Jan 14, 2010 | M.D. Anderson Cancer Center | No accrual. | Enrollment / accrual |
| NCT00803842 | Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash | N/A | withdrawn | Dec 8, 2008 | Northwestern University | Investigator left the institution and decided not to continue with the study. | Investigator |
| NCT00564876 | Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage…(TOP0706) | Phase 2 | terminated | Nov 28, 2007 | Duke University | Lack of accrual, study closed. | Enrollment / accrual |
| NCT01647334 | Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer | N/A | terminated | Jul 23, 2012 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Poor accrual | Enrollment / accrual |
| NCT00535275 | NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy | Phase 3 | terminated | Sep 26, 2007 | Intergroupe Francophone de Cancerologie Thoracique | Final analysis done, follow-up of patients no more necessary | Other (stated, no rule matched) |
| NCT00633568 | Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer | Phase 3 | terminated | Mar 12, 2008 | European Lung Cancer Working Party | Slow recruitment | Enrollment / accrual |
| NCT00661011 | Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung… | Phase 2 | terminated | Apr 18, 2008 | European Lung Cancer Working Party | The study was terminated due to too slow recruitment | Enrollment / accrual |
| NCT00818675 | A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat… | Phase 2 | terminated | Jan 8, 2009 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01046383 | Effect of IMN1207 Versus Casein on Weight Loss, Survival and Quality of Life in Non-small… | Phase 3 | terminated | Jan 12, 2010 | Immunotec Inc. | Slower than anticipated recruitment | Enrollment / accrual |
| NCT02297425 | A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer | Phase 2 | withdrawn | Nov 21, 2014 | Pfizer | not stated | Not stated |
| NCT00511576 | Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for… | Phase 1 | terminated | Aug 6, 2007 | Mirati Therapeutics Inc. | Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All… | Other (stated, no rule matched) |
| NCT00975767 | A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced… | Phase 1 | terminated | Sep 11, 2009 | Mirati Therapeutics Inc. | The study was terminated due to a need for a reformulation of the study drug. Phase 1 completed, no… | Enrollment / accrual |
| NCT01761747 | Ponatinib for Squamous Cell Lung and Head and Neck Cancers | Phase 2 / Phase 3 | terminated | Jan 7, 2013 | Dana-Farber Cancer Institute | FDA hold and toxicity associated with study drug | Safety / toxicity |
| NCT01336543 | Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III… | Phase 2 | withdrawn | Apr 18, 2011 | Syed Jafri | Low accrual, small patient population at center. | Enrollment / accrual |
| NCT00452075 | Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for… | Phase 2 | terminated | Mar 26, 2007 | Rigshospitalet, Denmark | Poor recruitment | Enrollment / accrual |
| NCT01664663 | Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis…(PLANET) | Phase 2 | terminated | Aug 14, 2012 | Ass. Prof. Jan Nyman | Safety analysis showed increased grade 5 toxicity in experimental arm. | Safety / toxicity |
| NCT01038037 | First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer(Lung-TRIO) | Phase 2 | terminated | Dec 23, 2009 | Vejle Hospital | 1. Very low enrollment rate. 2. Recent studies question the effect of adding panitumumab in this… | Safety / toxicity |
| NCT00549328 | Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer | Phase 2 | terminated | Oct 25, 2007 | GlaxoSmithKline | Study enrolment was delayed in starting and too slow to support further development in this setting | Enrollment / accrual |
| NCT01799161 | Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients… | Phase 1 | withdrawn | Feb 26, 2013 | Eckhard Podack | Insufficient funding | Funding |
| NCT00300885 | A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel… | Phase 3 | terminated | Mar 10, 2006 | Bayer | Based on the results of the interim analysis, it was determined that the study would not meet its… | Efficacy / futility |
| NCT00108186 | Celecoxib Treatment for Lung Cancer | Phase 1 | withdrawn | Apr 15, 2005 | US Department of Veterans Affairs | Couldn't accrue patients | Enrollment / accrual |
| NCT01049776 | GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line | Phase 2 | terminated | Jan 14, 2010 | Illinois CancerCare, P.C. | Study was terminated due to positive results seen in statistical analysis. Adequate patient… | Enrollment / accrual |
| NCT02127372 | Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571 | Phase 1 / Phase 2 | terminated | Apr 30, 2014 | Duke University | The study was closed due to poor accrual | Enrollment / accrual |
| NCT00509366 | Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV…(TOP0602) | Phase 2 | terminated | Jul 31, 2007 | Duke University | Study terminated due to reproducibility issues with genomics prediction model. | Other (stated, no rule matched) |
| NCT02209727 | Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic… | Phase 1 | terminated | Aug 6, 2014 | Boehringer Ingelheim | not stated | Not stated |
| NCT00787852 | A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung… | Phase 1 | terminated | Nov 10, 2008 | Brown University | for efficacy and safety reasons | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 14, 2015source: clinicaltrials